WuXi Biologics expects a sharp rise in full-year earnings for 2025, forecasting a 46.3 per cent increase in profit as it secures more projects across the drug development value chain, from discovery through to manufacturing.
In a positive profit alert filed with the Hong Kong stock exchange on Wednesday, the company said profit attributable to equity shareholders would reach about 4.91 billion yuan (US$710 million), while revenue is set to climb 16.7 per cent to 21.79 billion yuan.
Shares rose…
